Thu, Sep 18, 2014, 4:46 AM EDT - U.S. Markets open in 4 hrs 44 mins

Recent

% | $
Quotes you view appear here for quick access.

GTX Inc. Message Board

countonresearch 435 posts  |  Last Activity: Aug 8, 2014 11:59 PM Member since: Jun 11, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • countonresearch by countonresearch Aug 8, 2014 11:59 PM Flag

    Other than the trash spewed by the guy who answers his own posts. Insiders are loading up, Check out the new form 4’s

    Sentiment: Strong Buy

  • countonresearch countonresearch Aug 8, 2014 11:57 PM Flag

    Hey Rocky,
    I think you should quit while you’re ahead… The people who tracked your IP address and identified you as squirrel_fever, meet_me_at_the_flamingo, and dilution_solution_provider just might seek your physical address and post it. Good luck…

    Sentiment: Strong Buy

  • Reply to

    HUGE drop in Shorts!!!!

    by shriffle Jul 24, 2014 5:11 PM
    countonresearch countonresearch Jul 25, 2014 8:04 AM Flag

    It may be even lower than the 7/15 figure considering Wednesday's action.

    Sentiment: Strong Buy

  • countonresearch by countonresearch Jul 23, 2014 6:47 AM Flag

    Project Manager, Medical Affairs
    Senior Clinical Project Manager

    Sentiment: Strong Buy

  • Reply to

    Rocky aka

    by countonresearch Jun 2, 2014 12:06 PM
    countonresearch countonresearch Jul 8, 2014 10:27 AM Flag

    more like this

    Sentiment: Strong Buy

  • countonresearch by countonresearch Jun 27, 2014 8:23 AM Flag

    Pitt Hyde & Mason Hawkins Buy 50% Stake In GTx Ahead Of Phase II Results
    Apr. 29, 2014 8:40 AM ET | About: GTXI, Includes: AGEN, AZO, ECYT, OXGN
    Disclosure: I am long GTXI. (More...)
    Summary

    GTXI has recently seen extraordinary insider buying and outside investment of $38 million.
    Investors Pitt Hyde and Mason Hawkins have a successful track record of identifying undervalued companies poised for growth.
    New investments in GTXI coincide with imminent catalyst of the release of Phase II trial results for metastatic cancer drug, Enobosarm.
    Based on recent, positive Phase II trial results for other cancer drugs in sector, the average near-term gain is 109% post results release.
    Pitt Hyde & Mason Hawkins Take Over 50% Stake in GTx Ahead of Phase II Results

    In the recent, severe sell-off in biotech stocks, speculative investors are looking for bargains in the sector and signs of a bottom. With so many stocks suffering, it is very hard to navigate the many choices and pick which companies are buys at today's prices. The average retail investor does not have the time to do hours of research on hundreds of companies in their quest to find undervalued gems.

    Sentiment: Strong Buy

  • countonresearch by countonresearch Jun 25, 2014 6:04 AM Flag

    Look at the 4:00 pm sell off, five days in a row.

  • Reply to

    Dalton........

    by resurrection001 Jun 12, 2014 11:05 AM
    countonresearch countonresearch Jun 12, 2014 11:17 AM Flag

    He was probably told to leave, the research is over. Why give up a cushy job, with a nice salary? Most people sell shares when they need money, 79k is small amount. You don’t see Steiner or Hyde selling any do you?

    Sentiment: Strong Buy

  • Reply to

    This message board

    by countonresearch Jun 12, 2014 7:10 AM
    countonresearch countonresearch Jun 12, 2014 7:27 AM Flag

    Thanks for the welcome, I have not made a move yet, but have been considering adding this to my portfolio. One good sign is that at least the management refuted the article immediately. If they did nothing, I would be concerned. Good luck on your upcoming data.

  • countonresearch by countonresearch Jun 12, 2014 7:10 AM Flag

    Has to be one of the most active, with strong conviction on both sides. It looks like upcoming data is like placing all on black or red for the longs. However you won’t lose it all. Risk/reward, ?

    54% of the float being short is an overcrowded space. Shorts still have to buy their way out. Risk/reward, very questionable.

    I hold no position but have been reading your MB. GLTA….

  • countonresearch countonresearch Jun 4, 2014 2:38 PM Flag

    Click on "Market pulse" you will find realistic opinions

    Sentiment: Strong Buy

  • Reply to

    Rocky aka

    by countonresearch Jun 2, 2014 12:04 PM
    countonresearch countonresearch Jun 2, 2014 12:16 PM Flag

    Those people who invested when you showed up as squirrel_fever didn't loose money?

  • countonresearch by countonresearch Jun 2, 2014 12:06 PM Flag

    Squirrel_fever, who pumped GTXI and OPXA to go to the teens is now dilution_solution_provider and meet_me_at_flamingo posting endless bashing posts.

  • countonresearch by countonresearch Jun 2, 2014 12:04 PM Flag

    Squirrel_fever, who pumped GTXI and OPXA to go to the teens is now dilution_solution_provider and meet_me_at_flamingo posting endless bashing posts.

    Sentiment: Strong Buy

  • Reply to

    Results

    by countonresearch Jun 2, 2014 11:10 AM
    countonresearch countonresearch Jun 2, 2014 11:38 AM Flag

    "The primary endpoint was assessed in 17 AR+ patients with 6 patients demonstrating clinical benefit at six months, exceeding the pre-defined statistical threshold requiring that at least 3 of 14 patients with an AR+ metastatic lesion demonstrate clinical benefit".

    At what point do people realize that these results exceed the the required end points for phase II?

    Sentiment: Strong Buy

  • countonresearch by countonresearch Jun 2, 2014 11:10 AM Flag

    GTx, Inc. announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm, a selective androgen receptor modulator, for the treatment of patients with androgen receptor positive and estrogen receptorpositive metastatic breast cancer who have previously responded to hormonal therapy. The clinical data is being presented today during the Breast Cancer-HER2/ER poster session at the 50th Annual Meeting of the American Society of Clinical Oncolog in Chicago. The Phase 2 open-label study is evaluating 22 postmenopausal women with ER positive metastatic breast cancer, who had previously responded to adjuvant hormonal therapy for three years or longer, and women diagnosed with metastatic disease, who had been treated with hormonal therapy for at least six months, prior to disease progression. Study participants were heavily pretreated. The mean time from initial breast cancer diagnosis is 11 years and the mean age of patients is 64 years. Of the 22 patients enrolled in the study, a total of 20 patients had one or more scheduled assessments for determination of clinical benefit. The primary endpoint was assessed in 17 AR+ patients with 6 patients demonstrating clinical benefit at six months, exceeding the pre-defined statistical threshold requiring that at least 3 of 14 patients with an AR+ metastatic lesion demonstrate clinical benefit. Additionally, results showed that, after a median duration on study of 81 days, 41 percent of all patients achieved clinical benefit as best response and also had increased prostate specific antigen, which appears to be an indicator of AR activity.

    Sentiment: Strong Buy

  • At least wait for the catalyst. PR will come out after the presentation.

    Sentiment: Strong Buy

  • Or will it remain status quo, where analysts act like sports announcers, giving you an opinion after the fact.

    Sentiment: Strong Buy

  • Reply to

    Enobosarm study question

    by slaterx154 May 28, 2014 11:25 PM
    countonresearch countonresearch May 29, 2014 9:04 AM Flag

    The big difference between the statements is the use of "Will" and "Expects" to meet the pre-specified goal.

    Copy and paste of recent report from GTX Inc.
    “The Company has determined that the study WILL meet the pre-specified goal of demonstrating at least three clinical benefit responses in a minimum of 14 patients with AR positive metastatic breast cancer. The study is ongoing and the last study patient is expected to have her primary endpoint visit in June of this year, with data to assess the primary study endpoint expected in July 2014. Preliminary data from the study is being presented at the American Society of Clinical Oncology (ASCO) in Chicago, Illinois on June 2, 2014

    Copy and Paste of previous report.
    The Company EXPECTS to meet the pre-specified goal of demonstrating at least three clinical benefit responses in a minimum of 14 patients with AR positive metastatic breast cancer. The study is ongoing and data from all patients in the study is expected late in the second quarter of 2014”.

    Sentiment: Strong Buy

  • Reply to

    $150 million dilution??

    by orangedigit May 28, 2014 11:34 AM
    countonresearch countonresearch May 28, 2014 1:52 PM Flag

    Too funny

    Sentiment: Strong Buy

GTXI
0.7402-0.0504(-6.37%)Sep 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.